NCT02258217View on ClinicalTrials.gov

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NACompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 24, 2016

Study Completion Date

December 31, 2016

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Acthar

Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.

Trial Locations (1)

43214

OhioHealth, Columbus

Sponsors

Lead Sponsor

All Listed Sponsors

lead

OhioHealth

OTHER

NCT02258217 - Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) | Biotech Hunter | Biotech Hunter